Unlocking the Code: The Role of Molecular and Genetic Profiling in Revolutionizing Glioblastoma Treatment DOI Creative Commons
Moustafa Mansour,

Ahmed M Kamer-Eldawla,

Reem W Malaeb

и другие.

Cancer Treatment and Research Communications, Год журнала: 2024, Номер 43, С. 100881 - 100881

Опубликована: Янв. 1, 2024

Glioblastoma (GBM) is the most aggressive primary brain cancer, characterized by profound molecular and cellular heterogeneity, which contributes to its resistance conventional therapies poor prognosis. Despite multimodal treatments including surgical resection, radiation, chemotherapy, median survival remains approximately 15 months. Recent advances in genetic profiling have elucidated key alterations subtypes of GBM, such as EGFR amplification, PTEN ATRX loss, TP53 alterations, significant prognostic therapeutic implications. These discoveries spurred development targeted aimed at disrupting aberrant signaling pathways like RTK/RAS/PI3K TP53. However, treatment a formidable challenge, driven tumor complex microenvironment (TME), intrinsic adaptive mechanisms. Emerging approaches aim address these challenges, use immunotherapies immune checkpoint inhibitors CAR T-cell therapies, target specific antigens but face hurdles due immunosuppressive TME. Additionally, novel strategies biopolymer-based interstitial focused ultrasound for blood-brain barrier disruption, nanoparticle-based drug delivery systems show promise enhancing efficacy precision GBM treatments. This review explores evolving landscape therapy, emphasizing importance personalized medicine through profiling, potential combination need innovative overcome resistance. Continued research into GBM's biology modalities offers hope improving patient outcomes.

Язык: Английский

The road ahead for chimeric antigen receptor T cells DOI
Carli M. Stewart, Elizabeth L. Siegler, Saad S. Kenderian

и другие.

The Journal of Immunology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Abstract Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, field made significant progress our understanding successes challenges associated CART therapy. In this review, we provide overview current state clinic. We detail including patient access, CART-associated toxicity, tumor heterogeneity, trafficking, microenvironment, different fates. With each challenge, review lessons learned, potential solutions outline areas for future development. Finally, discuss how engineered moving into treatment solid tumors other diseases beyond cancer.

Язык: Английский

Процитировано

0

CAR-T cell therapy: breakthroughs, challenges and emerging horizons in cancer treatment DOI Open Access
Rajeev Goel

International Journal of Research in Medical Sciences, Год журнала: 2024, Номер 12(12), С. 4829 - 4841

Опубликована: Ноя. 30, 2024

Chimeric Antigen Receptor (CAR)-T cell therapy has recently emerged as a breakthrough technology, offering targeted approach in the treatment of cancers. It is form cancer immunotherapy which involves genetic modification autogenic or allogenic T cells to express chimeric receptor that can target specific tumor antigen on malignant cells. The receptors are because both antigen-binding and activating functions integrated into single receptor. greatest potential CAR-T lies its power use patient’s immune system fight besides durability. also overcomes certain limitations such limited effectiveness resistant cancers, lack precision blood cancers etc. associated with traditional therapies like chemotherapy radiation. proven significantly efficacious clinical trials for patients relapsed refractory haematological malignancies lesser extent solid tumors too. A few these CAR- have finally been approved by FDA after decades pre-clinical developments. though causes long term remissions some patients, yet either relapse suffer severe toxic adverse effects, leaving innovation space further research. This review discusses structure cells, principle applications, efficacy, safety, challenges future directions patients.

Язык: Английский

Процитировано

0

Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies DOI Creative Commons
Anna Fleischer,

S Kurth,

Johannes Duell

и другие.

Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(12), С. e009174 - e009174

Опубликована: Дек. 1, 2024

Background Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative modality in the treatment of patients with cancer. However, it is increasingly evident that this therapeutic approach not without its challenges. The unique nature CAR-T cells living drugs introduces distinct set side effects. As application expands to treat broader range diseases, becomes important devise effective strategies for handling associated toxicities. Challenges treating include addressing complications such cytokine release syndrome, immune effector cell-associated neurotoxicity and cytopenias. This comprehensive review seeks systematically identify, categorize elucidate all previously described neurological psychological effects therapy, shedding light on pertinent laboratory findings underscore these phenomena. Methods PubMed, Springer Link, ScienceDirect were searched empirical studies adult cancer receiving hemato-oncological malignancies. Quality assessment was conducted using Version 2 Cochrane risk-of-bias tool (RoB 2) randomized trials adherence STROBE (Strengthening Reporting Observational Studies Epidemiology) checklist observational studies. synthesis via narrative approach, consolidating diverse array data into coherent framework. Results From an initial pool 2,276 citations, 546 met inclusion criteria, exhibiting rich tapestry heterogeneity terms study characteristics patient samples. incidence neuropsychological symptoms varied notably across different products hematological Among most frequently reported aphasia, attention deficits, impaired consciousness, disorientation, alongside constellation other including confusion, cognitive impairment, memory loss, writing difficulties, fatigue, headache, agitation, tremor, seizures, psychomotor retardation. Early intervention strategies, corticosteroids tocilizumab, have shown potential reduce intensity prevent their progression critical complications. Conclusion These insights imperative extending assessments beyond conventional Immune Effector Cell-Associated Encephalopathy score

Язык: Английский

Процитировано

0

Unlocking the Code: The Role of Molecular and Genetic Profiling in Revolutionizing Glioblastoma Treatment DOI Creative Commons
Moustafa Mansour,

Ahmed M Kamer-Eldawla,

Reem W Malaeb

и другие.

Cancer Treatment and Research Communications, Год журнала: 2024, Номер 43, С. 100881 - 100881

Опубликована: Янв. 1, 2024

Glioblastoma (GBM) is the most aggressive primary brain cancer, characterized by profound molecular and cellular heterogeneity, which contributes to its resistance conventional therapies poor prognosis. Despite multimodal treatments including surgical resection, radiation, chemotherapy, median survival remains approximately 15 months. Recent advances in genetic profiling have elucidated key alterations subtypes of GBM, such as EGFR amplification, PTEN ATRX loss, TP53 alterations, significant prognostic therapeutic implications. These discoveries spurred development targeted aimed at disrupting aberrant signaling pathways like RTK/RAS/PI3K TP53. However, treatment a formidable challenge, driven tumor complex microenvironment (TME), intrinsic adaptive mechanisms. Emerging approaches aim address these challenges, use immunotherapies immune checkpoint inhibitors CAR T-cell therapies, target specific antigens but face hurdles due immunosuppressive TME. Additionally, novel strategies biopolymer-based interstitial focused ultrasound for blood-brain barrier disruption, nanoparticle-based drug delivery systems show promise enhancing efficacy precision GBM treatments. This review explores evolving landscape therapy, emphasizing importance personalized medicine through profiling, potential combination need innovative overcome resistance. Continued research into GBM's biology modalities offers hope improving patient outcomes.

Язык: Английский

Процитировано

0